Navigation Links
Women's health-related scientific findings presented by University of Pittsburgh researchers
Date:3/27/2008

SAN DIEGO, March 27 The clinical and basic science research findings of nearly two dozen studies are being presented by researchers from the University of Pittsburgh-affiliated Magee-Womens Research Institute (MWRI) at the 55th annual meeting of the Society for Gynecologic Investigation (SGI). In addition, James M. Roberts, M.D., MWRI founding director, will be honored during the sessions, which take place March 26 to 29 at the Manchester Grand Hyatt, San Diego.

An internationally known authority on the potentially deadly pregnancy complication preeclampsia, Dr. Roberts will receive the societys 2008 Frederick Naftolin Award for Mentorship. Established in 2003 to recognize contributions to the training and career development of investigators in the field of reproductive and womens health, the award is named for former SGI President Frederick Naftolin, M.D., Ph.D., of New York University.

It is indeed an honor to receive this award, said Dr. Roberts, professor and vice chairman of research in the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine. American medicine has somewhat belatedly realized the importance of gender-based research for women, but each year, more young investigators discover this vital area of study. It is a great privilege to be part of this process of discovery.

Some 5 percent of first pregnancies are complicated by preeclampsia, a condition characterized by soaring blood pressure and protein in the urine that is a leading cause of maternal, fetal and neonatal disability and death, particularly in undeveloped countries and among disadvantaged populations.

Among the findings being presented are:

Obstetricians quick to point out tobaccos dangers; less likely to talk about alcohol, drugs

A study of conversational points covered during patients first obstetric visits has revealed that physicians and other caregivers are
'/>"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Human Proteinpedia, a portal to share human protein data among the scientific community
2. UTSA receives $822,000 from Kleberg Foundation to enhance scientific research
3. Major scientific push to tackle agricultural productivity and food security in developing world
4. Scientific evidence supporting evolution continues to grow
5. Evolution education is a must says coalition of scientific and teaching organizations
6. PNNLs Richard Smith named to prestigious Scientific American 50 list of outstanding leaders
7. Canadian Society of Exercise Physiology Annual Scientific Conference
8. New ETH Zurich article published in scientific journal Nature
9. HortTalks, a valuable scientific resource
10. Scientists launch deep-sea scientific drilling program to study volatile earthquake zone
11. Frontiers in Optics presents scientific advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
(Date:9/17/2014)... including MRSA and MSSA could be curbed by ... the scaly surface of shark skin, according to ... Antimicrobial Resistance and Infection Control . , The ... spread of human disease bacteria through touching, sneezes ... arrangement of ridges formulated to resemble shark skin. ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3Sharks' skin has teeth in the fight against hospital superbugs 2
... real cost of Herceptin is borne by other patients whose ... doctors in this week’s BMJ. , New guidance from the ... (Herceptin) in early breast cancer, but it provides no extra ... to release this extra money. This leaves medical staff with ...
... larvae, warmed in a toasty lab chamber, are giving Cornell ... see how genes are expressed in living tissue. , Using ... Watt W. Webb, researchers have for the first time been ... activate their genes to synthesize key proteins in fruit fly ...
... protein converts chemical energy to mechanical force, thus powering ... structural model by University of North Carolina at Chapel ... a scientific mystery: how the protein dynein fuels itself ... include mitosis, or cell division into identical cells. ...
Cached Biology News:Other patients bear the real cost of Herceptin 2Researchers use multiphoton microscopy to watch chromosomes in action 2Researchers use multiphoton microscopy to watch chromosomes in action 3UNC scientists solve mystery of how largest cellular motor protein powers movement 2
(Date:9/17/2014)... VIENNA , Sept. 17, 2014 ... compelling, quantitative data from a study of the cost ... at the 50 th Annual Meeting of the ... a poster session today, Christian Frois , Ph.D., ... in a series of planned Intarcia-sponsored, retrospective studies to ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
(Date:9/17/2014)... 17 de septiembre de 2014  Cryoport, ... proveedor mundial de soluciones logísticas avanzadas criogénicas ... la vida, anunció hoy la contratación de ... con sede en Rótterdam, Países Bajos, para ... Europa en rápido crecimiento. Según los términos ...
(Date:9/17/2014)... Scotland , September 17, 2014 /PRNewswire/ ... new mode of action from a truly ... decade  MGB Biopharma, a biopharmaceutical ... anti-infectives, announces today that it has secured ... its lead antibacterial, MGB-BP-3, against a range ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... , , , ... NGSX ), a biopharmaceutical company focused on developing and commercializing ... Goodwin to its Board of Directors as a director and Audit ... President and CEO of Keren Pharmaceutical, a company focused on exploiting ...
... , , , WALTHAM, ... leading research and advisory firms for pharmaceutical and healthcare issues, ... most notably Novartis,s Diovan -- the hypertension drug market will ... the market will decrease by 1.4 percent annually and thereafter ...
... , GAITHERSBURG, Md., Aug. 25 GenVec, Inc. (Nasdaq: ... Phase 2 Small Business Innovation and Research (SBIR) grant from the ... Institutes of Health (NIH) to support the development of GenVec,s vector ... http://www.newscom.com/cgi-bin/prnh/ 2 0081205/DC50112LOGO ) , , ...
Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents 2GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development 2